Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 + Adebrelimab in Advanced Esophageal Cancer
NCT06474468Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-A2102 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Hengrui Therapeutics. Started Jun 2024; status: recruiting.
02
Drugs
SHR-A2102
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06474468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06474468.